Myasthenia Gravis Disease Market Research Report Information By Diagnosis (Imaging, Blood Tests, Electrodiagnostic, and Edrophonium Test), By Treatment (Medication, Surgery, and HSCT), By End-User (Hospitals, Clinics, and Academic Research Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032.

Global Myasthenia Gravis Disease Market Overview

Myasthenia Gravis Disease Market Size was valued at USD 1.15 billion in 2022. The Myasthenia Gravis Disease market industry is projected to grow from USD 1.23 Billion in 2023 to USD 1.97 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.9% during the forecast period (2023 - 2032). Key factors driving this market include the rising popularity of immunotherapies, approval of promising drugs, the emergence of biologics, and growing awareness about rare diseases. These are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Myasthenia Gravis Disease Market Trends

• Robust efforts by critical players toward novel therapies are boosting the market growth

Myasthenia gravis (MG) is a chronic, progressive, and rare neuromuscular disorder characterized by weakness of the head, extremities, spine, eyes, and respiratory muscles. In this autoimmune disease, antibodies are produced against the acetylcholine receptor (AchR), which blocks the standard transmission of electrical signals from nerves to muscles.

According to the National Organization for Rare Disorders (NORD), about 14-40 people in the United States have myasthenia gravis per 100,000 people. Reports indicate that the disease frequency has increased over the past few decades. This can be attributed to better identification of patients and the general prevalence of autoimmune diseases worldwide.

Myasthenia gravis occurs more frequently in women than in men, and although symptoms can appear at any age, its peak incidence is usually in men in their 50s or 60s and women in their 20s or 30s. There is no effective cure for myasthenia gravis, but symptoms can be managed with medication and surgery.

Research is focused on better understanding the specifics of autoimmune problems associated with MG and improving their diagnosis and Treatment. Additionally, the market is watching a paradigm shift in the research field from suppressing the immune system to rebalancing it. Another critical area of ​​research is the physiology of the neuromuscular junction (NMJ) to improve its function regardless of possible immune system attack. Therefore, the Myasthenia Gravis Disease market CAGR has been increasing ly in recent years. These are essential factors driving the Myasthenia Gravis Disease market revenue growth.

Myasthenia Gravis Disease Market Segment Insights

Myasthenia Gravis Disease Diagnosis Insights

Based on the Diagnosis, the Myasthenia Gravis Disease market segmentation includes Imaging, Blood Tests, Electrodiagnostic, and Edrophonium tests. The blood test segment held the majority share 2022 of the Myasthenia Gravis Disease market revenue. The primary test for myasthenia gravis is a blood test that looks for a type of antibody (produced by the immune system) that blocks signals from being sent between nerves and muscles. High levels of these antibodies usually mean you have myasthenia gravis.

Figure 1 Myasthenia Gravis Disease Market by Diagnosis, 2022 & 2030 (USD billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Myasthenia Gravis Disease Treatment Insights

Based on Treatment, the  Myasthenia Gravis Disease market segmentation includes Medication, Surgery, and HSCT. The medication segment held the majority share in 2022 of the  Myasthenia Gravis Disease market revenue. This is because the drug can significantly suppress the immune system and control associated symptoms to a great extent. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). The other main form of Treatment is surgery, which is the most invasive and usually involves thymectomy (thymectomy). The thymus gland degenerates with age (thymic involution), but total loss of the thymus gland in this way can significantly weaken the patient's immune system.

Myasthenia Gravis Disease End-User Insights

Based on End-User, the  Myasthenia Gravis Disease industry has been segmented into Hospitals, Clinics, and Academic Research Institutes. The hospital segment held the largest market share and is expected to grow at the highest CAGR during the forecast period. This can be attributed to access to a large patient pool and the high demand for advanced equipment for MG treatment in hospital settings. There has been an increase in patient visits for the diagnosis and Treatment of MG owing to the wide range of treatment options available in such facilities. Moreover, one of the significant factors contributing to its colossal share is the rising investment in state-of-the-art healthcare infrastructure.

Myasthenia Gravis Disease Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Myasthenia Gravis Disease market accounted for USD 0.52 billion in 2022. This can be attributed to the widespread adoption of immunotherapies and monoclonal antibodies, rising healthcare spending, established R&D facilities, and favorable reimbursement scenarios.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 MYASTHENIA GRAVIS DISEASE MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Myasthenia Gravis Disease market accounts for the second-largest market share. This is due to increased funding and institutions in various medical institutions to diagnose and treat rare diseases such as myasthenia gravis. Moreover, the rising prevalence and diagnosis of the disease in the Region have led to increased efforts by key players to develop new treatments. All these factors mentioned above are expected to drive the market over the forecast period. Further, the Germany Myasthenia Gravis Disease market held the largest market share, and the U.K. Myasthenia Gravis Disease market was the fastest-growing market in the European Region.

The Asia-Pacific Myasthenia Gravis Disease Market is expected to grow at the fastest CAGR from 2022 to 2030. Rising disease incidence in the Region, coupled with better treatment payment policies, is increasing diagnosis rates and the number of people receiving Treatment. According to a 2020 article published in the Taiwan Medical Association Journal, myasthenia gravis accounts for approximately 8.1% of Australia's top ten indications for IVIg. These factors are expected to drive the market growth in this Region. Finally, the rest of the world is expected to witness slow growth throughout the forecast perdue to healthcare infrastructure developmentture and lack of favorable reimbursement regulations for myasthenia gravis treatment. Moreover, the China Myasthenia Gravis Disease market held the largest market share, and the India Myasthenia Gravis Disease market was the fastest-growing market in the Asia-Pacific region.

Myasthenia Gravis Disease Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their product lines, which will help the Myasthenia Gravis Disease market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Myasthenia Gravis Disease industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the  Myasthenia Gravis Disease industry to benefit clients and expand the market sector. The Myasthenia Gravis Disease industry has provided medicine with some of the most significant benefits in recent years. Major players such as Valeant Pharmaceuticals International (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), and others are working on expanding the market demand by investing in research and development activities.

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma), an Indian multinational pharmaceutical company headquartered in Mumbai, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries the world. It is the largest pharmaceutical company in India and the world's fourth-largest specialty generic drug company. These products are indicated in various therapeutic areas covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dentistry, and nutrition. Its active drug products include baricitinib, brivaracetam, and dapagliflozin.

Also, Novartis Pharmaceuticals Corporation operates as a pharmaceutical company. The company researches, develops, manufactures, and markets patent-protected prescription medicines to address essential health needs in the cardiovascular, central nervous system, cancer, ophthalmology, organ transplant, and respiratory areas.

Key Companies in the Myasthenia Gravis Disease market include

• Apollo Endosurgery Inc.


• Johnson & Johnson Services Inc.


• Olympus Corporation


• ALLERGAN


• TransEnterix Surgical, Inc.


• Cousin Biotech


• EndoGastric Solutions, Inc.


• ReShape Lifesciences, Inc.


• Medtronic


• Intuitive Surgical


• Aspire Bariatrics


• Mediflex Surgical Products, among others

Myasthenia Gravis Disease Industry Developments

December 2021 Vyvgart (efgartigimod) is approved by the FDA for the Treatment of generalized myasthenia gravis (gMG) in individuals who test positive for anti-acetylcholine receptor (AChR) antibodies.

February 2021 Horizon Therapeutics announced a $3.05 billion acquisition of Viela Bio, developer of ibalizumab, a prospective therapy for autoimmune diseases such as myasthenia gravis (MG).

Myasthenia Gravis Disease Market Segmentation

Myasthenia Gravis Disease Diagnosis Outlook

• Imaging


• Blood Tests


• Electrodiagnostic


• Edrophonium Test

Myasthenia Gravis Disease Treatment Outlook

• Medication


• Surgery


• HSCT

Myasthenia Gravis Disease End-Userr Outlook

• Hospitals


• Clinics


• Academic Research Institutes

Myasthenia Gravis Disease Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America